Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SunRISe-1: TAR-200 and Cetrelimab in High-Risk NMIBC
NCT04640623Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2020
- Primary completion
- Jul 2025
- Modality
- Immune Checkpoint Inhibitors, Device-based Delivery, Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised trial of gemcitabine-releasing intravesical system and cetrelimab in non-muscle-invasive bladder cancer (NMIBC) (4 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Overall Complete Response Rate up to 50 months and Disease-free Survival up to 50 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT04640623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04640623.